31.95
price down icon1.30%   -0.42
after-market  시간 외 거래:  31.95 
loading

Arvinas Inc 주식(ARVN)의 최신 뉴스

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

pulisher
GlobeNewswire Inc.

Acadia (ACHC), Geisinger JV Begin Construction of New Hospital

pulisher
Zacks Investment Research

Absci (ABSI) to Report Q1 Earnings: Here's What to Expect

pulisher
Zacks Investment Research

Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates

pulisher
Zacks Investment Research

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

pulisher
GlobeNewswire Inc.

Why Earnings Season Could Be Great for Arvinas (ARVN)

pulisher
Zacks Investment Research

Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock?

pulisher
Zacks Investment Research

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline

pulisher
Zacks Investment Research

Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

pulisher
Zacks Investment Research

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

pulisher
GlobeNewswire Inc.

Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised

pulisher
Zacks Investment Research

Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate

pulisher
Zacks Investment Research

Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer

pulisher
GlobeNewswire Inc.

Is Arvinas (ARVN) Stock a Solid Choice Right Now?

pulisher
Zacks Investment Research

Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer

pulisher
GlobeNewswire Inc.

Arvinas to Participate in Upcoming Investor Conferences

pulisher
GlobeNewswire Inc.

Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

pulisher
Benzinga

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday

pulisher
Benzinga

Is a Surprise Coming for Arvinas (ARVN) This Earnings Season?

pulisher
Zacks Investment Research

Navigating 7 Analyst Ratings For Arvinas

pulisher
Benzinga

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates

pulisher
Zacks Investment Research

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

pulisher
GlobeNewswire Inc.

Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High?

pulisher
Zacks Investment Research

What Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now?

pulisher
Zacks Investment Research

Arvinas Announces Chief Financial Officer Transition

pulisher
GlobeNewswire Inc.

Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease

pulisher
GlobeNewswire Inc.

SPS Commerce Posts Upbeat Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Friday

pulisher
Benzinga

Can Tenet's (THC) Q4 Earnings Beat on Rising Patient Admissions?

pulisher
Zacks Investment Research

Wall Street Analysts Think Arvinas, Inc. (ARVN) Could Surge 26.67%: Read This Before Placing a Bet

pulisher
Zacks Investment Research

Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer

pulisher
GlobeNewswire Inc.

Encompass Health (EHC) to Post Q4 Earnings: What's in Store?

pulisher
Zacks Investment Research

Arvinas, Inc. (ARVN) Soars 10.0%: Is Further Upside Left in the Stock?

pulisher
Zacks Investment Research

Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference

pulisher
GlobeNewswire Inc.

Will High Medical Costs Affect Centene's (CNC) Q4 Earnings?

pulisher
Zacks Investment Research

Eaton Posts Strong Results, Joins Ferrari, Boot Barn And Other Big Stocks Moving Higher On Thursday

pulisher
Benzinga

Forecasting The Future: 6 Analyst Projections For Arvinas

pulisher
Benzinga

Cigna (CI) to Report Q4 Earnings: Can Rising Expenses Hurt?

pulisher
Zacks Investment Research

Can Higher Costs Affect HCA Healthcare's (HCA) Q4 Earnings?

pulisher
Zacks Investment Research

What Makes Arvinas, Inc. (ARVN) a New Strong Buy Stock

pulisher
Zacks Investment Research

Arvinas Appoints Jared Freedberg as General Counsel

pulisher
GlobeNewswire Inc.

Arvinas, Inc. (ARVN) Just Flashed Golden Cross Signal: Do You Buy?

pulisher
Zacks Investment Research

Is Arvinas (ARVN) Outperforming Other Medical Stocks This Year?

pulisher
Zacks Investment Research

Wall Street Analysts Believe Arvinas, Inc. (ARVN) Could Rally 42.05%: Here's is How to Trade

pulisher
Zacks Investment Research

Expert Outlook: Arvinas Through The Eyes Of 9 Analysts

pulisher
Benzinga

Has Arvinas (ARVN) Outpaced Other Medical Stocks This Year?

pulisher
Zacks Investment Research

Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session

pulisher
Benzinga

Torrid Reports Upbeat Results, Joins MBIA, Virco Mfg. And Other Big Stocks Moving Higher On Friday

pulisher
Benzinga

Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

pulisher
Benzinga

Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study

pulisher
Zacks Investment Research

THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On Wednesday

pulisher
Benzinga
$81.72
price down icon 0.13%
$28.81
price up icon 0.03%
$168.64
price up icon 2.55%
$151.37
price down icon 0.60%
$92.06
price up icon 2.14%
$382.55
price down icon 0.91%
자본화:     |  볼륨(24시간):